Business
Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases
Formosa Pharmaceuticals, Inc. ("Formosa", 6838.TW) and the Singapore Eye Research Institute ("SERI") are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa's proprietary APNT® (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI's world-class clinical research expertise, led by renowned Clinician Scientist, Associate Professor Yu-Chi Liu, MD, PhD.
About this update from Formosa Laboratories, Inc.
[{"type":"text","content":"SINGAPORE and TAIPEI, April 30, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. ("Formosa", 6838.TW) and the Singapore Eye Research Institute ("SERI") are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa's proprietary APNT® (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI's world-class clinical research expertise, led by renowned Clinician Scientist, Associate Professor Yu-Chi Liu, MD, PhD.","length":542,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Formosa Pharmaceuticals Inc.,)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Formosa Pharmaceuticals Inc.,)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":121,"url":"https://media.zenfs.com/en/prnewswire.com/df2f2b8e7dc998aaa222bb4fda4ccb64"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3.jl4P8tiI53C3CniNpzXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMw--/https://media.zenfs.com/en/prnewswire.com/df2f2b8e7dc998aaa222bb4fda4ccb64","width":400,"height":121}},"href":"https://mma.prnewswire.com/media/2002027/1_1_1_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative and clinically validated drug delivery platforms with deep clinical insights, the joint effort seeks to enhance the efficacy, bioavailability, and safety of topical ocular therapies, bringing new therapies to clinical practice.","length":366,"tagName":"p"},{"type":"text","content":"Synergy of Innovation and Clinical Excellence","length":45,"tagName":"p"},{"type":"text","content":"A/Prof Yu-Chi Liu, clinician scientist at Singapore National Eye Center and Principal Investigator at SERI, brings extensive experience in corneal neuropathy and translational medicine to the collaboration. Her recent work in diabetic keratopathy and ocular surface inflammation will be pivotal in guiding the development of formulations targeting complex anterior segment conditions.","length":384,"tagName":"p"},{"type":"text","content":""Collaborating with Formosa Pharmaceuticals allows us to bridge the gap between benchside innovation and bedside application," said A/Prof. Yu-Chi L...